Legal & General Group Plc Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Legal & General Group Plc lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 21.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 313,804 shares of the biopharmaceutical company’s stock after purchasing an additional 54,837 shares during the period. Legal & General Group Plc’s holdings in Ultragenyx Pharmaceutical were worth $11,410,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Mackenzie Financial Corp raised its position in Ultragenyx Pharmaceutical by 15.8% during the 1st quarter. Mackenzie Financial Corp now owns 18,658 shares of the biopharmaceutical company’s stock valued at $676,000 after purchasing an additional 2,543 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 231.4% during the first quarter. PNC Financial Services Group Inc. now owns 2,737 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 1,911 shares during the period. Deutsche Bank AG raised its holdings in shares of Ultragenyx Pharmaceutical by 0.5% in the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after acquiring an additional 8,385 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical in the first quarter worth about $59,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Ultragenyx Pharmaceutical by 8.4% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,342 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 493 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 2.9%

NASDAQ RARE opened at $34.75 on Monday. The firm’s fifty day simple moving average is $32.23 and its two-hundred day simple moving average is $32.39. The firm has a market capitalization of $3.35 billion, a P/E ratio of -6.28 and a beta of 0.30. Ultragenyx Pharmaceutical Inc. has a 12-month low of $25.81 and a 12-month high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. During the same period in the previous year, the business earned ($1.40) EPS. The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at $3,095,132.77. This trade represents a 7.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 10,456 shares of company stock worth $328,486. Corporate insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on RARE shares. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Truist Financial reduced their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Wells Fargo & Company initiated coverage on Ultragenyx Pharmaceutical in a research report on Monday, October 20th. They set an “overweight” rating and a $65.00 target price on the stock. Barclays cut their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.23.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.